'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics
Portfolio Pulse from Avi Kapoor
Jim Cramer discussed several companies on CNBC's 'Mad Money Lightning Round.' He described ADMA Biologics as a speculative investment despite its strong earnings report. MP Materials was noted for its need to recover from losses, while Delcath Systems was labeled as speculative despite positive study results.
August 30, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ADMA Biologics reported strong Q2 earnings, beating estimates and raising future revenue guidance. Despite this, Jim Cramer considers it a speculative investment.
ADMA Biologics reported better-than-expected earnings and raised future guidance, which is typically positive for stock prices. However, Jim Cramer's speculative comment may temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Delcath Systems announced positive study results but is still considered speculative by Jim Cramer. The stock gained 1.2%.
Positive study results are a good sign, but the speculative nature of the company as noted by Jim Cramer may limit immediate stock impact.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
MP Materials needs to recover from a series of losses, as highlighted by Jim Cramer. The stock gained 3.2% recently.
Despite recent stock gains, MP Materials is under pressure to recover from losses, which could impact future performance.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80